Skip to main content

Table 1 Inclusion and exclusion criteria

From: A treat and extend protocol with Aflibercept for cystoid macular oedema secondary to central retinal vein occlusion – an 18-month prospective cohort study

Inclusion Criteria

  Age ≥ 18 years

  CRVO with CMO as determined by fluorescein angiography and duration of onset less than 12 months

  BCVA of 17–70 ETDRS letters (20/40–20/400)

  CMT ≥300 μm as measured by OCT

  Absent relative afferent pupillary defect

Exclusion Criteria

 Systemic

  Uncontrolled blood pressure (≥180 mmHg systolic and 110 mmHg diastolic)

  Chronic renal failure

  Major surgery within 1 month of study entry

  Previous systemic anti-VEGF treatment

  Women of childbearing age not using adequate contraception and women who are breast feeding

  Intercurrent severe disease such as septicaemia

 Ocular

  Glaucoma which is uncontrolled with IOP-lowering medications

  Past history of severe steroid response with IOP ≥ 35 mmHg following steroid treatment

  Loss of vision due to other causes (e.g. age-related macular degeneration, myopic macular degeneration)

  BCVA of < 20/200 in the fellow eye

  Argon laser photocoagulation within 3 months of study entry

  Previous intraocular surgery within 6 months of study entry

  Stroke or myocardial infarction less than 3 months prior to study entry

  Any active periocular or ocular infection or inflammation at screening or baseline.

  Subjects, who in the opinion of the Investigator, may not benefit from treatment due to pre-existing or current macular condition (eg, vitreomacular traction, epiretinal membrane, scar, foveal atrophy)

  1. CRVO central retinal vein occlusion, CMO cystoid macular oedema, BCVA best-crrected visual acuity, ETDRS Early Treatment of Diabetic Retinopathy Study, CMT central macular thickness, OCT optical coherence tomography, IOP intraocular pressure